Mirati’s Adagrasib Takes The Lead Among KRAS G12C Inhibitors In CRC
Monotherapy, Combo Data Outshine Amgen’s Lumakras
Adagrasib may carve out a niche as the superior drug in colorectal cancer, but lung cancer – where Lumakras already is approved – is a larger market where Amgen has a big lead.
